drugset / Trial / NCT00633685
Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
Phase 4
Unknown
300 enrolled
TEMPVA Research Group, Inc.
C.R.Darnall Army Medical Center · collabCentral Texas Veterans Health Care System · collabVA Boston Healthcare System · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Three hundred (300) male or female outpatients, over 18 years of age, will be enrolled in this study to determine whether fluoxetine can be used as a treatment for Posttraumatic Stress Disorder in soldiers recently returning from combat exposure. There will be two phases to the study. In Phase I Fluoxetine + usual psychological care will be compared with Placebo + usual psychological care over a 12-week period. Subsequently, in Phase II all subjects will be offered the opportunity to enroll in a 20-week open-label trial on Fluoxetine. If response is inadequate, adjunctive treatment with either buspirone or bupropion will be offered. The investigational drugs are Fluoxetine, Buspirone and Bupropion. All are commercially available.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-06
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluoxetine | Small molecule | 20 mg | — |
| Subject | Fluoxetine | Small molecule | 60 mg | — |
| Subject | Fluoxetine | Small molecule | 80 mg | — |